Key Takeaways
- “Brain tumour” is not one diagnosis. Glioma, metastasis, meningioma, lymphoma, pituitary-region tumour and other lesions have different reasons for biopsy, resection, observation, systemic treatment or radiotherapy.
- The operative principle is maximal safe resection, not the largest possible removal at any neurological cost. The plan should name the function at risk and how it will be protected.
- A stereotactic biopsy and an open resection answer different questions. Biopsy may be preferable when the lesion is deep, diffuse, highly treatment-sensitive or unsafe to remove.
- Modern CNS tumour diagnosis integrates microscopic and molecular findings. For many tumours, a label based only on appearance is incomplete under WHO CNS5.[3][4]
- The multidisciplinary decision must include what happens after surgery: postoperative MRI, integrated pathology, radiotherapy or systemic therapy, rehabilitation and management of seizures or steroids.
- International patients should take home the DICOM images, navigation-quality scans, operative map, tissue and molecular report, paraffin block or slide access process, and an executable adjuvant-treatment timetable.
Content
Brain tumour surgery has several possible purposes: obtain a diagnosis, relieve pressure, reduce tumour burden, control seizures, preserve neurological function or create a safer route to radiotherapy and drug treatment. Those purposes are not automatically aligned. Removing more tissue may improve one objective while worsening language, memory, vision, movement or independence.
For a patient considering surgery in China, the most useful comparison is therefore not a surgeon's annual case count or a promise of “total removal” alone. It is whether a neuro-oncology team can explain the tumour hypothesis, the safest tissue strategy, the functional boundary and the treatment that will follow the pathology result.
Treat sudden deterioration as an emergency, not a travel-planning problem
New weakness, speech or vision loss, a prolonged or first seizure, repeated vomiting, severe escalating headache, reduced consciousness or abrupt personality change can reflect bleeding, hydrocephalus, cerebral oedema or seizure activity. The patient needs urgent local assessment rather than waiting for an overseas appointment.
Steroids can reduce vasogenic oedema in selected patients but do not treat every intracranial lesion and can change symptoms, glucose, infection risk and even the diagnostic yield of suspected CNS lymphoma. Antiseizure medication is also diagnosis- and event-specific. Do not start, stop or taper either group solely to fit a flight date.
Define the tumour hypothesis before choosing an operation
The MRI description “space-occupying lesion” is only a starting point. Ask the team to rank plausible diagnoses and identify the evidence for each. Important distinctions include:
- primary infiltrating glioma versus circumscribed tumour;
- a solitary or multiple brain metastasis from systemic cancer;
- extra-axial lesions such as meningioma;
- primary CNS lymphoma, infection, demyelination or vascular mimic;
- pituitary, skull-base, ventricular or posterior-fossa origin; and
- newly diagnosed versus recurrent or treatment-related change.
NCI notes that imaging patterns can be misleading and that tissue confirmation is important in most suspected primary CNS tumours, while selected lesions that are very likely benign may be monitored and some locations may be unsafe to biopsy.[2] A radiological guess should not be presented as a final tumour name.
Assemble imaging that can support navigation and comparison
Send the original DICOM studies, not screenshots embedded in a report. The preoperative set may include contrast-enhanced 3D T1, T2, FLAIR, diffusion and susceptibility sequences, with perfusion, spectroscopy, functional MRI or tractography selected for a specific question. NICE defines T2, FLAIR, DWI and pre- and post-contrast T1 volume imaging as the minimum initial structural MRI for suspected glioma.[1]
The team should review:
- lesion volume, enhancement, diffusion, haemorrhage and necrosis;
- surrounding FLAIR abnormality and mass effect;
- eloquent cortex, deep nuclei, white-matter tracts and vessels;
- ventricular obstruction or hydrocephalus;
- prior radiation field and serial growth; and
- for suspected metastasis, number and total intracranial volume plus extracranial disease status.
If the scan will be used for navigation, confirm whether a new thin-slice study is needed and how recent it must be. Keep every prior scan with its acquisition date so that growth is assessed from comparable sequences rather than memory.
Make the multidisciplinary meeting real
A meaningful brain tumour conference brings the actual images and clinical record to the table. Core contributors usually include neurosurgery, neuro-oncology or medical oncology, radiation oncology, neuroradiology and neuropathology. Rehabilitation, epilepsy, endocrinology, ophthalmology, genetics, palliative care or paediatric/young-adult expertise should join when the location and diagnosis require them.
The written output should state:
- leading and alternative diagnoses;
- whether observation, biopsy, resection, systemic therapy or radiotherapy is recommended first;
- functional and medical risks that shaped the decision;
- tests still missing;
- how unexpected intraoperative findings would change the plan; and
- the next treatment branch for each likely pathology result.
For suspected brain metastasis, NICE advises intracranial and appropriate extracranial imaging before the neuro-oncology MDT; the primary tumour, molecular profile, extracranial control, performance status, number, volume and location all affect treatment.[1] A brain-only plan can be wrong even when the cranial operation is technically feasible.
Compare biopsy and resection by the question each answers
Stereotactic biopsy obtains targeted tissue through a small opening. It may suit a deep, diffuse or multifocal lesion, suspected lymphoma, a patient with limited reserve, or a case in which diagnosis will determine non-surgical treatment. Its limitations include small sample volume, sampling error and insufficient tissue for all molecular studies if the plan is poor.
Open resection can provide more tissue, decompress the brain and reduce tumour burden. It also carries a larger neurological, bleeding, infection and recovery burden. A resectable metastasis may provide current pathology and rapid symptom relief, while stereotactic radiosurgery may be preferable for other locations or clinical situations; NICE recommends weighing size, location, oedema, comorbidity, systemic disease and patient preference.[1]
Ask before consent:
- what the procedure is intended to accomplish;
- where the biopsy target or resection boundary lies;
- what tissue volume pathology and molecular laboratories require;
- which finding would cause the surgeon to stop;
- what result could make the first procedure non-diagnostic; and
- whether a second operation could still be necessary.
“Small incision” does not mean small diagnostic uncertainty, and “complete resection” is meaningless unless the imaging compartment and tumour type are named.
Define maximal safe resection in functional terms
For infiltrating glioma, tumour cells can extend beyond visible or enhancing margins. Surgery alone rarely eliminates all malignant infiltrating disease.[2] The 2026 EANS–EANO guideline links extent of resection to postoperative imaging and stresses that neurological status, cognition, quality of life, epilepsy and downstream radio- and pharmacotherapy all belong in the decision.[6]
The surgeon should identify the proposed endpoint—for example, contrast-enhancing tumour, a FLAIR-defined region or decompression only—and the function that limits it. Techniques may include navigation, intraoperative ultrasound or MRI, fluorescence guidance, cortical and subcortical stimulation mapping, neurophysiological monitoring and awake testing. Each has a role and a blind spot.
Awake craniotomy is not inherently superior; it is useful when real-time language or higher-function testing is needed and the patient can participate safely. An asleep operation with mapping and monitoring may be appropriate for other targets. Tractography is a model of likely fibre pathways, not a live proof that every fibre is safe. Fluorescence can help visualise certain tumour tissue but does not define every infiltrating cell or functional border.
Plan the specimen before the first cut
WHO's fifth-edition CNS classification integrates histopathology with molecular pathology, and many tumour entities require an integrated histomolecular diagnosis.[3][4][5] The operating and laboratory teams should agree on specimen identity and allocation in advance.
For a suspected diffuse glioma, the required panel depends on age, location and morphology but may include IDH status, ATRX, 1p/19q codeletion, MGMT promoter methylation and other alterations needed to establish or refine a WHO diagnosis. These tests are not a universal consumer bundle: each should serve classification, prognosis, treatment or trial eligibility.
The final report should distinguish:
- intraoperative provisional diagnosis;
- histological description and grade;
- molecular tests performed, methods and results;
- final integrated WHO diagnosis;
- results still pending or technically unsuccessful; and
- whether material remains for external review or future testing.
Frozen-section language should not be mistaken for the final diagnosis. If the result is “not otherwise specified” or otherwise incomplete, ask whether the limitation is missing testing, inadequate tissue or a genuinely unclassifiable tumour.
Prepare for surgical branches and early complications
The preoperative plan should cover current neurological baseline, cognitive and language function, seizures, steroid exposure, anticoagulants, infection, nutrition, venous-thromboembolism risk, blood availability and postoperative level of care. Discuss fertility preservation before treatment when radiation or systemic therapy may affect it.[1]
Consent should separate general risks—anaesthesia, bleeding, infection, clots—from location-specific risks such as aphasia, memory change, weakness, visual-field loss, cranial-nerve deficit, endocrine dysfunction or swallowing problems. It should also address seizures, CSF leak, hydrocephalus, wound healing, reoperation and the possibility that the planned extent cannot be achieved safely.
Families need a contact pathway for worsening headache, repeated vomiting, new deficit, seizure, wound leakage, fever, increasing drowsiness or calf/chest symptoms after discharge.
Use postoperative MRI and examination as the new baseline
The operative note should record the actual procedure, residual area intentionally left, mapping results, unexpected events and implants. For glioma, NICE recommends considering a baseline MRI within 72 hours of resection.[1] Timing and sequences matter because postoperative enhancement, blood products and later treatment effects complicate interpretation.
The early assessment should pair images with function:
- consciousness, language, memory, motor and visual findings;
- seizure events and medication changes;
- steroid dose and taper conditions;
- mobility, swallowing, self-care and rehabilitation needs;
- wound and infection status; and
- pathology and molecular-result timetable.
A radiology phrase such as “gross total resection” should be checked against the preoperative target compartment and formal volumetric or descriptive assessment. It is not a guarantee that an infiltrating tumour has been cured.
Connect surgery to the next treatment without losing weeks
Adjuvant treatment depends on the integrated diagnosis, grade, molecular findings, age, performance and residual disease. Glioblastoma, IDH-mutant astrocytoma, oligodendroglioma, meningioma, lymphoma and metastasis have different pathways. Surgery should not be sold as a self-contained package.
Before discharge, schedule the pathology conference and identify who will prescribe radiotherapy, systemic therapy, tumour-treating fields where relevant, rehabilitation and supportive care. For metastasis, the systemic cancer team must decide how intracranial and extracranial treatment interact. For a resection cavity, radiation planning may require the preoperative and immediate postoperative images plus the operative description.
NICE recommends neurological rehabilitation assessment at diagnosis and at every stage of follow-up when needed.[1] Cognitive, language, visual, motor, fatigue and emotional changes can be treatment priorities even when the scan looks satisfactory.
Make the cross-border handover reproducible
CDC advises medical travellers to arrange follow-up before travel and obtain complete records in English.[7] A brain-tumour handover should contain:
- chronological clinical summary and current neurological examination;
- all MRI/CT/PET DICOM files and formal reports;
- MDT conclusion and operative intent;
- operative report, mapping and monitoring summary, navigation screenshots if available and implant details;
- early postoperative MRI and the surgeon's residual-disease map;
- full integrated pathology and molecular laboratory reports;
- specimen block/slide identifiers and the process for external review;
- generic medication list, steroid taper, seizure and emergency plan;
- rehabilitation assessment and current assistance level; and
- dates and decision points for radiation, systemic therapy and surveillance.
Do not fly because a package itinerary says the hospital stay is over. Fitness to travel depends on neurological stability, seizures, intracranial air, wound condition, mobility and thrombosis risk, and should be documented by the treating team.
Medical disclaimer: This article provides general education. It cannot identify a brain lesion, decide between biopsy and resection, define a safe functional margin, interpret molecular pathology or determine fitness to fly. Acute neurological deterioration or a prolonged seizure requires urgent local care.
FAQ
Does every brain tumour need to be removed completely?
No. Some lesions are observed, biopsied, treated systemically or irradiated; infiltrating tumours may not have a removable border. The goal is diagnosis- and patient-specific maximal safe treatment, not removal at any neurological cost.
Why might a surgeon recommend biopsy instead of resection?
Biopsy may provide the diagnosis with less tissue disruption when a lesion is deep, diffuse, multifocal, suspected to be lymphoma or otherwise unsafe to remove. The team must still plan enough representative tissue for histology and molecular testing.
Is awake brain surgery always safer?
No. Awake mapping is valuable when real-time testing of language or other higher functions is needed and participation is safe. Other tumours are appropriately treated asleep with imaging, stimulation mapping and monitoring. The relevant question is how the function at risk will be tested.
Why is molecular testing needed after the pathologist sees the tumour?
WHO CNS5 defines many tumours by integrated microscopic and molecular features.[3][4] Molecular results can change the final name, grade, prognosis, adjuvant treatment or clinical-trial eligibility.
What should be available before starting radiotherapy at home?
The home team usually needs the integrated pathology, molecular results, pre- and early postoperative DICOM images, operative and residual-disease description, current neurological function, steroid and seizure plan, and any prior radiation records.
Sources
- National Institute for Health and Care Excellence — Brain Tumours and Brain Metastases in Over 16s (NG99)
- US National Cancer Institute — Central Nervous System Tumours Treatment (Health Professional PDQ)
- WHO/IARC — WHO Classification of Tumours: Central Nervous System Tumours, 5th Edition
- European Association of Neuro-Oncology — Molecular Diagnostic Tools for the WHO 2021 Classification
- National Health Commission of China — Clinical Guideline for Diagnosis and Treatment of Glioma (2022)
- EANS–EANO — Guidelines on the Extent of Resection in Gliomas (2026)
- US Centers for Disease Control and Prevention — Medical Tourism, Yellow Book 2026
Image Review
- Decision: Original image rejected; replacement pending as hero-reviewed.png.
- Editorial note: The current illustration is a generic consultation with a circular care-pathway graphic and a small brain icon. It does not show neuroradiology, operative planning, neuropathology or a genuine multidisciplinary tumour conference. The replacement should show several relevant specialists reviewing the same scan without displaying identifiable patient information or implying complete removal.